Effects of melatonin on blood pressure in stress-induced hypertension in rats.
Melatonin, acting through its receptors, is involved in numerous physiological processes, including blood pressure (BP) regulation. In present study, the effect of melatonin inhibition on stress-induced hypertension was investigated. The hypertensive model consisted of male Sprague-Dawley rats subjected to electrical foot-shock combined with noise. Microinjection of melatonin (0.1 and 1.0 mmol/L) into the anterior hypothalamic area (AHA) produced a fall in BP in nomortensive rats and stress-induced hypertensive rats (SIHR). Luzindole (10 mmol/L), a competitive antagonist of melatonin MT1 and MT2 receptors, almost completely abolished the depressor effect of melatonin, the MT2 receptor-specific antagonist 4-phenyl-2-propionamidotetralin (10 mmol/L) partially blocked (by approximately 60%) the depressor effect of melatonin, whereas the MT3 receptor-selective antagonist prazosin (10 mmol/L) failed to antagonize the effects of melatonin. Brain microdialysis was performed in the AHA and the rostral ventrolateral medulla (RVLM). Melatonin and amino acids in the dialysate samples collected were detected by high-performance liquid chromatography combined with fluorescence detection. The results indicated that melatonin concentrations in the AHA were reduced in SIHR. Microinjection of melatonin into the AHA decreased glutamate release and increased GABA and taurine release in the RVLM, which were paralleled by a decrease in arterial pressure. The mRNA expression of MT2 in the AHA of SIHR was higher than that in normotensive control rats, whereas there was no significant difference in MT1 mRNA expressin between the two groups. The results of the present study suggest that both a decrease of melatonin and an increase in the MT2 receptor in the AHA are involved in the manifestation of stress-induced hypertension. Both MT1 and MT2 receptors participated in the antihypertensive effect of melatonin in the AHA. The antihypertensive effect of melatonin was related to the decreases in the excitatory amino acid glutamate and increases in the inhibitory amino acids taurine and GABA in the RVLM.
Xia
Chun-Mei
CM
Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.
Shao
Ci-Hui
CH
Xin
Lin
L
Wang
Yang-Rong
YR
Ding
Chao-Nan
CN
Wang
Jin
J
Shen
Lin-Lin
LL
Li
Li
L
Cao
Yin-Xiang
YX
Zhu
Da-Nian
DN
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D003216:Conditioning, Operant; D004558:Electric Stimulation; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D007032:Hypothalamus, Anterior / Q000378:metabolism / Q000502:physiology; D008297:Male; D008550:Melatonin / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology*; D008845:Microinjections; D009622:Noise; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D044094:Receptors, Melatonin / Q000502:physiology; D013312:Stress, Physiological / Q000187:drug effects / Q000502:physiology*
D044094:Receptors, Melatonin; D008550:Melatonin